The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Bartlett
J Blake
JB
Celgene Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059, USA. bbartlett@celgene.com
Dredge
Keith
K
Dalgleish
Angus G
AG
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide; C467566:pomalidomide; D000077269:Lenalidomide